Skip to content
VuFind
Advanced
  • Prevalence and management of H...
  • Cite this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab
QR Code

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab

Bibliographic Details
Main Authors: Chan, Arlene, McGregor, S.
Format: Journal Article
Published: Blackwell Publishing 2012
Online Access:http://hdl.handle.net/20.500.11937/49060
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://hdl.handle.net/20.500.11937/49060

Similar Items

  • Adjuvant trastuzumab in HER2-positive breast cancer.
    by: Slamon, D., et al.
    Published: (2011)
  • Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
    by: Chan, Arlene, et al.
    Published: (2016)
  • Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study
    by: Au, H., et al.
    Published: (2013)
  • Trastuzumab biosimilar in early breast cancer setting: Will there be direct patient benefits?
    by: Chan, Arlene
    Published: (2017)
  • Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    by: Chan, Arlene, et al.
    Published: (2016)

Search Options

  • Advanced Search

Find More

  • Browse the Catalog

Need Help?

  • Search Tips